Table 6.
Functional impairment combined for epilepsy and psychosis
| Program | Control | ANCOVA | Full cohort (n = 156) T | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | (SD) | Mean | (SD) | Effect size F, partial eta2 |
P-val* | Mean | (SD) | Effect size Z, r |
P-val** | |
| WHODAS | 1.78, 0.01 | 0.18 | 7.83, 0.63 | < 0.0001 | ||||||
| Baseline | 39.9 | (22.8) | 31.2 | (23.8) | 37.8 | (23.2) | ||||
| end point | 15.4 | (21.8) | 19.4 | (28.7) | 16.3 | (23.6) | ||||
| Δ score | − 24.5 | (27.8) | − 11.8 | (33.5) | − 21.5 | (29.6) | ||||
| BAS | 0.01, < 0.01 | 0.92 | 10.56, 0.85 | < 0.0001 | ||||||
| Baseline | 74.4 | (8.1) | 72.2 | (9.2) | 73.9 | (8.4) | ||||
| end point | 60.4 | (6.9) | 59.6 | (8.1) | 60.2 | (7.2) | ||||
| Δ score | − 14.0 | (8.8) | − 12.6 | (10.0) | − 13.7 | (9.1) | ||||
WHODAS World Health Organization Disability Assessment Schedule 2.0 Short Version, BAS burden assessment schedule
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)